documents: FDA-2019-D-5255-0002

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2019-D-5255-0002 FDA FDA-2019-D-5255 Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability Notice Notice of Availability 2019-11-29T05:00:00Z 2019 11 2019-11-29T05:00:00Z 2020-01-29T04:59:59Z 2020-01-29T02:08:15Z 2019-25919 0 0 09000064841c88a5

Links from other tables